[Clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025)].

Abstract

IgA nephropathy (IgAN) is the most common primary glomerular disease in China and a leading cause of end-stage renal disease (uremia) in young adults. The diagnosis, prognostic assessment, and treatment strategies for IgAN and IgA vasculitis with nephritis (IgAVN) have been comprehensively evaluated by the Scientific Committee of the China IgA Nephropathy Network (IIgANN-China) and the Chinese Preventive Medicine Association's Committee for the Prevention and Control of Kidney Diseases based on recent literature and evidence-based medicine. As a result, clinical practice guidelines specifically tailored to Chinese patients have been developed. These guidelines introduce an integrated therapeutic framework that incorporates risk-stratified treatment, targeting both immune-mediated renal injury and chronic kidney disease progression, as well as stage-specific treatment, including both the induction and maintenance phases. The aim is to provide standardized guidance and practical recommendations for the clinical management of IgAN and IgAVN in China.

IgA肾病（IgAN）是我国最常见的原发性肾小球疾病，也是导致青壮年人终末期肾脏病（尿毒症）最常见的病因。由中国IgA肾病协作组（IIgANN-China）科学委员会委员和中华预防医学会肾脏病预防与控制专业委员会委员基于最新的文献和循证证据，对IgA肾病及IgA血管炎肾炎的疾病诊断、预后评估及治疗策略进行了充分的论证，制定了更适合中国患者的临床实践指南，提出IgA肾病的分层治疗（针对免疫损伤和慢性肾脏病进展）和分阶段治疗（诱导缓解治疗和维持治疗）的综合治疗理念，旨在为中国IgA肾病及IgA血管炎肾炎的规范化诊疗提供指导和参考。.